Thyroid Eye Disease Market Expands With Targeted Therapies and Improved Diagnosis

The cost of advanced biologic therapies and differences in reimbursement across countries represent additional challenges. Access to specialized ophthalmology and endocrinology services also varies geographically, potentially creating disparities in diagnosis and treatment.

For patients primarily concerned with proptosis and visible ocular changes, the unmet need extends beyond conventional exophthalmos treatment market approaches. Orbital decompression and reconstructive procedures may be considered in selected patients, but surgery can involve risks and may not address active inflammation. Consequently, pharmaceutical interventions capable of simultaneously reducing disease activity and ocular manifestations remain commercially attractive.

Emerging Therapies and Competitive Landscape

The TED pipeline is increasingly characterized by targeted therapies directed at immune pathways and disease mechanisms. DelveInsight identifies several promising candidates, including batoclimab, VRDN-001, and COSENTYX (secukinumab).

Batoclimab, developed by Immunovant, is a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). The therapy is designed to reduce pathogenic IgG antibodies and has been investigated as a potentially self-administered subcutaneous treatment. Its development illustrates the industry's focus on mechanisms beyond conventional immunosuppression and on delivery approaches that could improve patient convenience.

Viridian Therapeutics’ VRDN-001, or veligrotug, is another important pipeline candidate targeting IGF-1R. In May 2025, Viridian announced that the FDA granted Breakthrough Therapy Designation to veligrotug for TED, highlighting the potential importance of this candidate in the evolving treatment landscape.

Novartis’ cosentyx thyroid eye disease development represents another area of interest, particularly because secukinumab targets inflammatory pathways distinct from IGF-1R and FcRn approaches. The emergence of therapies with different mechanisms could intensify competition and potentially provide physicians with a broader range of options for patients with different disease characteristics.

Future Outlook for Thyroid Eye Disease Treatment

The future of TED management is expected to increasingly emphasize precision treatment, earlier diagnosis, and therapies that provide durable improvements in ocular outcomes. The shift from nonspecific immunosuppression toward targeted biological treatments could substantially reshape treatment algorithms over the coming years.

According to DelveInsight, the United States held the largest TED market in 2022, valued at approximately USD 1.98 billion, and this market is expected to increase through 2034. The report anticipates that TEPEZZA will remain an important component of the US treatment landscape, while emerging therapies such as batoclimab and other pipeline candidates may introduce additional competition.

At the same time, growing disease awareness could improve identification of patients who previously remained undiagnosed. Better understanding of disease mechanisms, advances in biomarkers, and greater collaboration between endocrinologists, ophthalmologists, and other specialists may further support individualized treatment decisions.